| __timestamp | Halozyme Therapeutics, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 5903000 |
| Thursday, January 1, 2015 | 29245000 | 2762000 |
| Friday, January 1, 2016 | 33206000 | 1114000 |
| Sunday, January 1, 2017 | 31152000 | 25573000 |
| Monday, January 1, 2018 | 10136000 | 6000000 |
| Tuesday, January 1, 2019 | 45546000 | 38845000 |
| Wednesday, January 1, 2020 | 43367000 | 50523000 |
| Friday, January 1, 2021 | 81413000 | 75463000 |
| Saturday, January 1, 2022 | 139304000 | 105767000 |
| Sunday, January 1, 2023 | 192361000 | 167512000 |
| Monday, January 1, 2024 | 159417000 |
Cracking the code
In the competitive landscape of biotechnology, cost efficiency is paramount. This analysis delves into the cost of revenue trends for Halozyme Therapeutics, Inc. and Xenon Pharmaceuticals Inc. from 2014 to 2023. Over this period, Halozyme's cost of revenue surged by approximately 747%, peaking in 2023. In contrast, Xenon experienced a 2,736% increase, highlighting a more volatile trajectory. Notably, 2021 marked a pivotal year, with both companies witnessing significant jumps in their cost structures. Halozyme's cost efficiency improved in the early years, but recent trends suggest a shift towards higher expenditure. Meanwhile, Xenon's costs have fluctuated, reflecting its dynamic growth strategy. This data underscores the importance of strategic financial management in sustaining competitive advantage in the biotech sector.
Cost of Revenue Comparison: AbbVie Inc. vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Sanofi vs Xenon Pharmaceuticals Inc.
Cost of Revenue Trends: Zoetis Inc. vs Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc.'s Expenses
Cost of Revenue Comparison: Insmed Incorporated vs Xenon Pharmaceuticals Inc.
Halozyme Therapeutics, Inc. vs Grifols, S.A.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Halozyme Therapeutics, Inc. vs Cytokinetics, Incorporated
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and MorphoSys AG
Cost of Revenue Comparison: Telix Pharmaceuticals Limited vs Xenon Pharmaceuticals Inc.
Cost of Revenue Comparison: PTC Therapeutics, Inc. vs Xenon Pharmaceuticals Inc.
Cost of Revenue: Key Insights for Xenon Pharmaceuticals Inc. and Wave Life Sciences Ltd.
Cost of Revenue Trends: Xenon Pharmaceuticals Inc. vs Dyne Therapeutics, Inc.